Elekta announced today that it entered into a joint venture with Sinopharm to increase the adoption of radiation therapy in China.
The initiative aims to bring radiation therapy to what’s considered lower-tier cities. These cities comprise approximately 70% of China’s population, according to a news release.
Elekta develops precision radiation therapy to treat cancer. The FDA cleared its latest offering, the Comprehensive Motion Management (CMM) with True Tracking and automatic gating, last month.
Shanghai-based Sinopharm (China National Pharmaceutical Group) covers all aspects of healthcare. Its pharmaceutical business is the second largest in the world, according to our sister publication Drug Discovery & Development‘s Pharma 50 report. In addition to drug development, Sinopharm operates a substantial China-based logistics network for drugs and medical devices. It engages in R&D, manufacturing, logistics, distribution and healthcare…